MAK683
Total Payments
$84,155
Transactions
4
Doctors
0
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2020 | $5.75 | 1 | 0 |
| 2019 | $28,890 | 1 | 0 |
| 2018 | $38,129 | 1 | 0 |
| 2017 | $17,130 | 1 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $84,155 | 4 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A PHASE I II MULTICENTER OPEN LABEL STUDY OF MAK683 IN ADULT PATIENTS WITH ADVANCED MALIGNANCIES | Novartis Pharmaceuticals Corporation | $84,155 | 0 |
Top Doctors Receiving Payments for MAK683
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | San Francisco, CA | $84,155 | 4 |
Ad
Manufacturing Companies
Product Information
- Type Drug
- Total Payments $84,155
- Total Doctors 0
- Transactions 4
About MAK683
MAK683 is a drug associated with $84,155 in payments to 0 healthcare providers, recorded across 4 transactions in the CMS Open Payments database. The primary manufacturer is Novartis Pharmaceuticals Corporation.
Payment data is available from 2017 to 2020. In 2020, $5.75 was paid across 1 transactions to 0 doctors.
The most common payment nature for MAK683 is "Unspecified" ($84,155, 100.0% of total).
MAK683 is associated with 1 research study, including "A PHASE I II MULTICENTER OPEN LABEL STUDY OF MAK683 IN ADULT PATIENTS WITH ADVANCED MALIGNANCIES" ($84,155).